Company
Headquarters: Stockholm, Sweden
Employees: 167
CEO: Ms. Isabelle Valerie Ghislaine Ducellier
kr12.57 Billion
SEK as of July 1, 2024
US$1.18 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
BioGaia AB has the following listings and related stock indices.
Stock: OMX: BIOG.B wb_incandescent
Stock: FSX: BGL wb_incandescent
Stock: OTC: BIOGY wb_incandescent